ArticleCell reports. Medicine2026

An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer.

Yunru Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.